Literature DB >> 17073900

Refractory glaucoma--tube or diode?

Rizwan Malik1, Roger B Ellingham, Hanif Suleman, William H Morgan.   

Abstract

BACKGROUND: The aim of the present study was to assess the relative effectiveness of tube surgery and cyclodiode laser in terms of achieving intraocular pressure control.
METHODS: A retrospective study was undertaken to compare patients undergoing double plate Molteno tube implantation with patients undergoing diode cyclophotocoagulation. Intraocular pressure (IOP) was documented at 7 days prior to surgery and postoperatively at various time points. Surgical success was defined as a final IOP between 6 (inclusive) and 21 mmHg (inclusive), without the use of topical medication, while 'qualified' success was defined as IOP within the same range with the use of topical medication.
RESULTS: Twenty-eight diode patients and 26 tube patients were included for the study. An average follow up of 150 weeks (range = 21-322 weeks) was available. Mean preoperative IOP was 37 +/- 12 mmHg for the tube group and 39 +/- 16 mmHg for the diode group (t = 0.51, P = 0.61). The final IOP was 17 +/- 12 mmHg for the tube group and 21 +/- 13 mmHg for the diode group (t = 0.35, P = 0.73). Surgical success was achieved in 46% of tube eyes and 11% of diode eyes, while qualified success was achieved in 81% of tube eyes compared with 64% of eyes in the diode group. Two eyes which underwent diode became phthisical.
CONCLUSIONS: IOP control may be achieved in a greater number of patients with tube surgery. The possible benefits of IOP control in diode patients need to be weighed against the risks of long-term visual loss and the need for multiple re-treatments in this group.

Entities:  

Mesh:

Year:  2006        PMID: 17073900     DOI: 10.1111/j.1442-9071.2006.01339.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  7 in total

1.  Intermediate term safety and efficacy of transscleral cyclophotocoagulation after tube shunt failure.

Authors:  Peter J Ness; Mahmoud A Khaimi; Robert M Feldman; Rania Tabet; Steven R Sarkisian; Gregory L Skuta; Alice Z Chuang; Kimberly A Mankiewicz
Journal:  J Glaucoma       Date:  2012-02       Impact factor: 2.503

2.  Transscleral diode laser cyclophotocoagulation for refractory glaucoma secondary to juvenile idiopathic arthritis: a short term follow-up.

Authors:  Anna I Dastiridou; Sofia Androudi; Anna Praidou; Periklis Brazitikos; Catherine G Brozou; Evangelia E Tsironi
Journal:  Int Ophthalmol       Date:  2012-11-16       Impact factor: 2.031

3.  Trans-scleral diode laser cyclophotocoagulation for refractory glaucoma after high-risk penetrating keratoplasty.

Authors:  Alejandro Rodríguez-García; Luis Alonso González-González; J Carlos Alvarez-Guzmán
Journal:  Int Ophthalmol       Date:  2015-09-29       Impact factor: 2.031

4.  A new manner of reporting pressure results after glaucoma surgery.

Authors:  Constantin-Dan Bordeianu; Cristina-Eugenia Ticu
Journal:  Clin Ophthalmol       Date:  2011-12-30

Review 5.  Cyclodestructive Procedures in Glaucoma: A Review of Current and Emerging Options.

Authors:  Anna I Dastiridou; Andreas Katsanos; Philippe Denis; Brian A Francis; Dimitrios G Mikropoulos; Miguel A Teus; Anastasios-Georgios Konstas
Journal:  Adv Ther       Date:  2018-11-17       Impact factor: 3.845

6.  Two-year efficacy after first transscleral controlled cyclophotocoagulation in patients with and without pseudoexfoliation.

Authors:  Markus Lenzhofer; Melchior Hohensinn; Wolfgang Hitzl; Veit Steiner; Armin Motaabbed; Karolina Motloch; Hans Peter Colvin; Herbert A Reitsamer; Sarah Moussa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-02       Impact factor: 3.117

7.  Long-term Outcomes of Ahmed Glaucoma Valve Implantation in Refractory Glaucoma at Farabi Eye Hospital, Tehran, Iran.

Authors:  Reza Zarei; Heidar Amini; Ramin Daneshvar; Fahimeh Naderi Nabi; Sasan Moghimi; Ghasem Fakhraee; Yadollah Eslami; Masoud Mohammadi; Nima Amini
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.